866-997-4948(US-Canada Toll Free)

PharmaPoint: Non-Small Cell Lung Cancer - Italy Drug Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jun 2013

Category :

Cancer

No. of Pages : 188 Pages


Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

The Italian NSCLC market is expected to decline due primarily to patent expirations of the major NSCLC marketed therapies Alimta, Avastin, Iressa and Tarceva combined with increasing price pressures from the Italian government.

Scope

  • Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Italy from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Italy NSCLC market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Italy.
Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 13

3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology and Histology 14
3.1.3 NSCLC Biomarkers 15
3.1.4 Quality of Life 16
3.2 Symptoms 17

4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Diagnosis 20
4.1.2 Clinical Staging 21
4.1.3 Screening and Early Detection 23
4.1.4 Localized Procedures and Therapies 24
4.1.5 Systemic Chemotherapy 25
4.1.6 Targeted Therapy 26
4.2 Italy 29
4.2.1 Diagnosis 29
4.2.2 Clinical Practice 29

5 Competitive Assessment 31
5.1 Overview 31
5.2 Strategic Competitor Assessment 32
5.3 Product Profiles Major Brands, Chemotherapies 34
5.3.1 Alimta (pemetrexed disodium) 34
5.4 Product Profiles Major Brands, Targeted Therapies 39
5.4.1 Iressa (gefitinib) 39
5.4.2 Tarceva (erlotinib hydrochloride) 44
5.4.3 Xalkori (crizotinib) 49
5.4.4 Avastin (bevacizumab) 53

6 Opportunity and Unmet Need 57
6.1 Overview 57
6.2 Improved Overall Survival and Less Toxicity 58
6.3 Treatments for Patients with Acquired TKI Resistance 59
6.4 Better Treatment Options for Squamous Patients 59
6.5 Preventing Relapse or Recurrence 60
6.6 More Efficacious Second-Line Therapies 60
6.7 Increased Availability of Mutation Testing 61
6.8 More Cost-Effective Therapies 62
6.9 Unmet Needs Gap Analysis 62

7 Pipeline Assessment 66
7.1 Overview 66
7.2 Promising Drugs in Clinical Development 66
7.2.1 onartuzumab (MetMab) 70
7.2.2 necitumumab (IMC-11F8) 76
7.2.3 ramucirumab (IMC-1121B) 81
7.2.4 custirsen (OGX-011) 85
7.2.5 ganetespib (STA-9090) 90
7.2.6 nintedanib (BIBF1120) 97
7.2.7 Gilotrif (afatinib) 101
7.2.8 dacomitinib (PF-00299804) 107
7.2.9 LDK378 111
7.2.10 Yervoy (ipilimumab) 116
7.2.11 nivolumab (BMS936558) 120
7.2.12 GSK1572932A (MAGE-A3 Cancer Immunotherapeutic) 126
7.2.13 Halaven (eribulin mesylate) 130

8 Market Outlook 135
8.1 Italy 135
8.1.1 Forecast 135
8.1.2 Key Events 138
8.1.3 Drivers and Barriers 139

9 Appendix 141
9.1 Bibliography 141
9.2 Abbreviations 160
9.3 Methodology 164
9.4 Forecasting Methodology 164
9.4.1 Number of NSCLC Patients Currently Seeking Treatment 164
9.4.2 Percent Drug-treated Patients 165
9.4.3 Drugs Included in Each Therapeutic Class 165
9.4.4 Launch and Patent Expiry Dates 166
9.4.5 General Pricing Assumptions 167
9.4.6 Individual Drug Assumptions 170
9.4.7 Generic Erosion 178
9.4.8 Pricing of Pipeline Agents 179
9.5 Physicians and Specialists Included in This Study 181
9.6 Survey of Prescribing Physicians 183
9.7 About the Authors 184
9.7.1 Authors 184
9.7.2 Epidemiologists 185
9.7.3 Global Head of Healthcare 186
9.8 About GlobalData 187
9.9 Disclaimer 187

List of Table


Table 1: Symptoms of Disease NSCLC 18
Table 2: Treatment Guidelines for NSCLC 20
Table 3: Stage Definitions for NSCLC 22
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 28
Table 5: Leading Treatments for NSCLC 34
Table 6: Product Profile Alimta (pemetrexed disodium) 36
Table 7: Alimta SWOT Analysis, 2013 38
Table 8: Product Profile Iressa (gefitinib) 41
Table 9: Iressa SWOT Analysis, 2013 43
Table 10: Product Profile Tarceva (erlotinib hydrochloride) 45
Table 11: Tarceva SWOT Analysis, 2013 48
Table 12: Product Profile Xalkori (crizotinib) 50
Table 13: Xalkori SWOT Analysis, 2013 53
Table 14: Product Profile Avastin (bevacizumab) 54
Table 15: Avastin SWOT Analysis, 2013 56
Table 16: Overall Unmet Needs Current Level of Attainment 58
Table 17: Clinical Unmet Needs Gap Analysis, 2013 63
Table 18: Non-Small Cell Lung Cancer Phase I-II Pipeline, 2013 67
Table 19: NSCLC Phase III Pipeline, 2013 68
Table 20: NSCLC Advantages and Disadvantages of Therapeutic Classes 69
Table 21: Product Profile onartuzumab (MetMab) 71
Table 22: onartuzumab SWOT Analysis, 2013 76
Table 23: Product Profile necitumumab (IMC-11F8) 77
Table 24: necitumumab SWOT Analysis, 2013 81
Table 25: Product Profile ramucirumab (IMC-1121B) 82
Table 26: ramucirumab SWOT Analysis, 2013 85
Table 27: Product Profile custirsen (OGX-011) 86
Table 28: custirsen SWOT Analysis, 2013 90
Table 29: Product Profile ganetespib (STA-9090) 91
Table 30: ganetespib SWOT Analysis, 2013 96
Table 31: Product Profile nintedanib (BIBF-1120) 97
Table 32: nintedanib SWOT Analysis, 2013 101
Table 33: Product Profile Gilotrif (afatinib) 102
Table 34: Gilotrif SWOT Analysis, 2013 106
Table 35: Product Profile dacomitinib (PF-00299804) 107
Table 36: dacomitinib SWOT Analysis, 2013 111
Table 37: Product Profile LDK378 112
Table 38: LDK378 SWOT Analysis, 2013 116
Table 39: Product Profile Yervoy (ipilimumab) 117
Table 40: Yervoy SWOT Analysis, 2013 120
Table 41: Product Profile nivolumab (BMS936558) 121
Table 42: nivolumab SWOT Analysis, 2013 126
Table 43: Product Profile GSK1572932A (MAGE-A3 immunotherapy) 127
Table 44: MAGE-A3 (GSK1572932A ) SWOT Analysis, 2013 130
Table 45: Product Profile Halaven (eribulin mesylate) 131
Table 46: Halaven SWOT Analysis, 2013 134
Table 47: Sales Forecasts ($m) for NSCLC in Italy, 2012-2022 136
Table 48: Key Events Impacting Sales for NSCLC in Italy, 2012-2022 138
Table 49: NSCLC Market in Italy Drivers and Barriers, 20122022 139
Table 50: Five Year Prevalence 165
Table 51: Key Launch Dates 166
Table 52: Key Patent Expiries 167
Table 53: Physicians Surveyed by Country 183

List of Chart


Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 20122022 69
Figure 2: Sales for NSCLC in Italy by Drug, 20122022 137

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *